Urea cycle modulation by combined SGLT2 inhibitors and metformin
COMBI therapy modulates amino acid metabolism, the urea cycle, and ketone body production, suggesting potential mechanisms underlying its protective effects against liver fibrosis and male subfertility. These findings provide novel insights into the systemic metabolic actions of COMBI therapy and highlight its translational potential to improve clinical outcomes in T2D patients.
Authors
- Martin Hrabě de Angelis (ORCID: https://orcid.org/0000-0002-7898-2353)
- Jutta Lintelmann (ORCID: https://orcid.org/0000-0002-0113-5746)
- Alexander Cecil (ORCID: https://orcid.org/0000-0002-1430-1790)
- Markus Scheerer
- Cornelia Prehn (ORCID: https://orcid.org/0000-0002-1274-4715)
- Makoto Harada (ORCID: https://orcid.org/0000-0002-6209-7683)
- Susanne Neschen
- Martin Irmler (ORCID: https://orcid.org/0000-0003-3169-479X)
- Wang-Sattler Rui
- Birgit Linkohr (ORCID: https://orcid.org/0000-0002-3387-5685)
- Johannes Beckers
- Annette Peters
- Siyu Han
- Christian Gieger
- Jerzy Adamski
- Michael Witting
- Sven Zukunft
- Daniel Teupser
- Jonathan Adam
- Jianhong Ge
- Mengya Shi
Institutions
- University of Ljubljana (SI)
- National University of Singapore (SG)
- Helmholtz Zentrum München (DE)
- LMU Klinikum (DE)
- German Centre for Cardiovascular Research (DE)
- Deutsches Diabetes-Zentrum e.V. (DE)
- German Center for Diabetes Research (DE)
- Heinrich Heine University Düsseldorf (DE)
- Tumkur University (IN)
- Technical University of Munich (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- BMC Medicine
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1186/s12916-025-04609-7
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00